RankAlpha logo
Back to Rankings

KLRS

Kalaris TherapeuticsB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The primary filings support a funded development path into late 2027, so the company has time to execute on TH103 without an immediate financing overhang. If enrollment and dose optimization keep progressing, the 1H 2027 data window can support a rerating before the cash runway becomes a problem.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Cash runway into Q4 2027 reduces near-term dilution pressure but does not remove financing risk if burn accelerates.
Momentum
74
Value
42
Sentiment
67
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.60 · Bull $8.00 · Bear $2.70
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-27 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $18.60
Why
Momentum74 · Δ7d -
Value42 · Δ7d +0.1
Sentiment67 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
74
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
42
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
67
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade B. Momentum 74.5 / Value 41.9 / Sentiment 66.8

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$106.96M
Beta
-0.10
Shares Out
18.7M
P/E (TTM) · Derived
-0.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.77
Rev YoY
-
EPS YoY
+97.7%
Gross Margin
-
Op Margin
-
Net Debt
-$118.29M
Current Ratio
12.89
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology